Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Boehringer Extends Alzheimer's Pact with Ablynx | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Boehringer Extends Alzheimer’s Pact with Ablynx

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Boehringer Ingelheim has extended research funding for another year in its Alzheimer’s disease collaboration with Ablynx. In January 2007 the companies entered into a $265 million worldwide research and licensing agreement to discover and develop new therapies for Alzheimer’s disease using Ablynx’s Nanobodies, a class of therapeutic proteins. The agreement included a joint research program with Ablynx scientists.

BI will be responsible for the development, manufacture and commercialization of any products resulting from the collaboration. As part of the collaboration, Ablynx received an upfront fee and will receive development and commercial milestones as well as undisclosed royalties based on net sales.
   
Dr. Edwin Moses, chief executive officer and chairman of Ablynx, commented, “We are very pleased with the progress that has been made in our joint Alzheimer’s disease program with BI. We look forward to continue working together with BI in this medical area which urgently requires an innovative approach.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters